Metabolic syndrome is a prevalent and serious disease that has been recognized recently. The term metabolic syndrome refers to a syndrome consisting of central obesity as indicated by excessive visceral fat, plasma lipid abnormalities, glucose dysregulation and high blood pressure. Schizophrenia is a dominant civil health issue that customarily nonce in the interim or anon adolescence. Antipsychotic medications is an imperative integral of the treatment of this disarray and research theorize that these drugs may be even spare constructive if given during the pioneer phase of illness. Second generation antipsychotics (SGA) have testify to scanty leverage over first generation antipsychotics(FGA) in terms of positive, negative, cognitive and affective symptoms and a lower proclivity if extrapyramidal symptoms. In contempt of these under inadmissible leverage, SGA have been associated with causing and exacerbating metabolic syndromes such as obesity, diabetes, and hyperlipidemia. Proper monitoring of metabolic parameters should be strictly followed. Life style management, drugs for controlling weight gain can be considered. There is a need for double blind studies, of long duration, with oral glucose tolerance test, other advanced tests and also to include children as group as there are reports to have a high liability for children to experience antipsychotic induced weight gain and associated metabolic disturbances.
Cite this article:
Parvathi K J, Ramalingam Kameswaran R, Sambathkumar R. Pshycotropic Drugs: A Persuader for Metabolic Syndromes. Research J. Pharm. and Tech 2020; 13(6): 2695-2698. doi: 10.5958/0974-360X.2020.00479.5
1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salomen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA. 2002; 288 : 2709-2716.
2. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research.2005; 80:19-32.
3. Marc A., De Hert. Prevalence of the metabolic syndrome in patients with schizophrenia treatedwith antipsychotic medication. Schizophrenia Res 2006; 83(1) : 87-93.
4. Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. Journal of Hypertension. 2006; 24 : 621-626.
5. M De Hert, R van Winkel, D Van Eyck, L Hanssens, M Wampers, A Scheen, and J Peuskens. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clinical Practice Epidemology and Mental Health. 2006; 2 :14.
6. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects:a comprehensive literature review. CNS Drugs 2005; 19 (1) : 1-93.
7. IlariaTarricone, Michela Casoria: Metabolic risk factor profile associated with use of second-generation antipsychotics: a cross sectional study in a community mental health center. BMC Psychiatry. 2006; 6 : 11.
8. JimRosack. Clinicians Urged to Better Monitor Drug-Related side effects. Psychiatry News.2006; 41 31.
9. Ya Mei Bai, Chao-Cheng Lin et al: Association of Initial Antipsychotic Response to Clozapine and Long-Term Weight Gain. American Journal of Psychiatry. 2006; 163 : 1276-1279.
10. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry.2004; 37: 1–11.
11. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2003; 17: S162–9.
12. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd, et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Research Bulletin. 2001; 55: 641–50.
13. Wetterling T. Bodyweight gain with atypical antipsychotics a comparative review. Drug Safety. 2001; 24(1):59-74.
14. Ardizzone TD, Bradley RJ, Freeman, Dwyer DS. Inhibition of glucose transport in pc12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Research. 2001; 923(1-2):82-90.
15. Margaret O, Sowell N, Mukhopadhyay, Patrizia, et al. Hyperglycaemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. The Journal of Clinical Endocrinology and Metabolism. 2002; 87(6):2918-23.
16. Bettingert TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. The Annals of Pharmacotherapy. 2000; 34(7):865-7.
17. Gianfrancesco F, White, Richard, et al. Antipsychotic induced type 2 diabetes: evidence from a large health plan database. Journal of Clinical Psychopharmacology. 2003; 23(4): 328-35.
18. Liao GY, An JJ, Gharami K, Waterhouse EG, Vanevski F, Jones KR, Xu B: Dendritically targeted mRNA is essential for energy balance and response to leptin. Nature Medicine. 2012; 18:564-571.
19. Holsboer F, Ising M: Stress hormone regulation: biological role and translation into therapy. Annual Research Psychology. 2010; 61:81-109.
20. Feder A, Nestler EJ, Charney DS: Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 2009; 10:446-457.
21. Kling MA, Coleman VH, Schulkin J: Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety. 2009; 26:641-649.
22. Boswell EB, Anfinson TH, Nemeroff CB: Depression associated with endocrine disorders; In Robertson MM, KatonaCLE(eds): Depression and physical illness. England: Wiley, Chichester, 1997, pp 256-292.
23. Bahls SC, de Carvalho GA : The relation between thyroid function and depression: a review. Rev BrasPsiquiatr 2004; 26:41-49.
24. Cleare AJ, McGregor A, O'Keane V: Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clinical Endocrinology. 1995; 43:713-719.
25. Frey A, Lampert A, Dietz K, Striebich S, Locher C, Fedorenko O, Möhle R, Gallinat J, Lang F, Lang UE:Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits. Neuropsychobiology. 2007; 56:123-126.
26. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC: Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry. 2001; 158:1617-1622.
27. Christopher K., McClellan. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA 2009; 302(16):1811-2.